Related Experiment Video
Updated: Oct 16, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.6K
Trial watch: intratumoral immunotherapy.
Juliette Humeau1,2, Julie Le Naour3,4,5, Lorenzo Galluzzi6,7,8,9
1Canada Department of Medicine, Institute for Research in Immunology and Cancer (Iric), Université de Montréal, Montreal, QC, Canada.
Oncoimmunology
|October 22, 2021
Summary
Immunotherapy, including immune checkpoint inhibitors, reactivates the immune system to fight cancer by priming T cells and enabling their effector functions. Intratumoral delivery enhances antitumor immunity with reduced toxicity.
Area of Science:
- Oncology
- Immunology
- Cancer Therapeutics
Background:
- Chemotherapy and radiotherapy are standard treatments for unresectable tumors.
- Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment over the last two decades.
- Immunotherapy aims to restore the body's natural anticancer immune response.
Purpose of the Study:
- To review the mechanisms of immunotherapy in cancer treatment.
- To highlight various immunotherapeutic strategies and their delivery methods.
- To discuss the potential of intratumoral delivery for enhanced efficacy and safety.
Main Methods:
- Review of current literature on cancer immunotherapy.
- Analysis of the two main phases of anticancer immune responses: priming and effector phases.
- Examination of different immunotherapeutic agents and delivery strategies.
Main Results:
- Immunotherapies leverage the immune system's priming and effector phases to combat cancer.
- A range of therapeutic approaches, including vaccines, antibodies, oncolytic viruses, and cell transfer, target different stages of the immune cascade.
- Intratumoral delivery is an emerging strategy to boost local antitumor immunity while minimizing systemic side effects.
Conclusions:
- Immunotherapy represents a significant advancement in cancer care, complementing traditional treatments.
- Understanding the intricacies of immune activation is crucial for developing effective immunotherapies.
- Intratumoral delivery holds promise for improving the therapeutic index of cancer immunotherapies.
